Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: The "rescue" approach

Cancer

Volumn 113, Issue 8, 2008, Pages 2152-2157

  Perry, James R ^a   Rizek, Philippe ^a   Cashman, Rosemary ^b   Morrison, Meredith ^a   Morrison, Tara ^c  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c FOX CHASE CANCER CENTER   (United States)

Author keywords

Brain neoplasms; Chemotherapy; Glioblastoma; Rechallenge; Temozolomide

Indexed keywords

TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; DRUG TOLERABILITY; FEMALE; GLIOBLASTOMA; GLIOMA; HERPES ZOSTER; HUMAN; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; THRUSH; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES;

EID: 55749094160     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23813     Document Type: Article

References (18)

1. Stupp R, Mason WP, Van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996.
2. Mirimanoff R, Mason W, Van den Bent M, et al. Is long-term survival in glioblastoma possible? Updated results of the EORTC/NCIC Phase III randomized trial on radiotherapy and concomitant and adjuvant temozolomide versus RT alone [abstract]. Int J Radiat Oncol Biol Phys. 2007;69(suppl 5):52.
3. Hegi M, Diserens A-C, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997-1003.
4. Gorlia T, Van den Bent M, Hegi M, et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE. 3. Lancet Oncol. 2008;9:29-38.
5. Butowski NA, Sneed P, Chang SM. Diagnosis and treatment of recurrent high-grade astrocytoma. J Clin Oncol. 2006;24:1273-1280.
6. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004;4:423-426.
7. Bertolini F, Paul S, Mancuso P, et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res. 2003;63:4342-4346.
8. Zhou Q, Guo P, Wang X, et al. Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens. J Pharmacol Exp Ther. 2007;321:265-275.
9. Mason WP, Del Maestro R, Eisenstat D, et al. Canadian recommendations for the treatment of glioblastoma multiforme. Curr Oncol. 2007;14:110-117.
10. Kandel MJ, Loehr A, Harter P, Traut A, Gravert K, duBois A. Cisplatinum rechallenge in relapsed ovarian cancer patients with platinum reinduction therapy and carboplatinum hypersensitivity. Int J Gynecol Cancer. 2005;15:780-784.
11. Yeoh C, Chau I, Cunningham D, Norman AR, Hill M, Ross PJ. Impact of 5-fluorouracil rechallenge on subsequent response and survival in advanced colorectal cancer: pooled analysis from 3 consecutive randomized controlled trials. Clin Colorectal Cancer. 2003;3:102-197.
12. Liu L, Gerson SL. Targeted modulation of MGMT: clinical implications. Clin Cancer Res. 2006;12:328-331.
13. Tolcher AW, Gerson SL, Denis L, et al. Marked inactivation of O6-alkylguanine-DNA-alkyltansferase activity with protracted temozolomide schedules. Br J Cancer. 2003;88:1004-1011.
14. Macdonald DR, Cascino TL, Schold SC, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277-1280.
15. Franceschi E, Omuro A, Lassman A, et al. Salvage temozolomide for prior temozolomide responders. Cancer. 2005;104:2473-2476.
16. Jauch T, Hau P, Bogdahn U. Re-challenge with temozolomide (TMZ) at recurrence in high-grade gliomas. Proc ASCO. 2007;25(18 suppl):83s.
17. Kong DS, Lee JI, Kim WS, et al. A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma. Oncol Rep. 2006;16:1117-1121.
18. Su YB, Sohn S, Krown SE, et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol. 2004;22:610-616.